Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...

A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions ...

A pharmacogenetics score may help physicians predict which patients with acute myeloid leukemia are more likely to respond to ...

The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.

Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier ...

ADX-2191 has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. About Primary Vitreoretinal Lymphoma Primary vitreoretinal lymphoma is a ...

BIA-ALCL is a type of T-cell lymphoma that arises near textured breast implants, either as a collection of fluid or mass. It usually develops seven to 10 years after women undergo mastectomy and ...

Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of non-Hodgkin's lymphomas and is a rare but aggressive form of T-cell lymphoma that usually occurs in children and young adults.

A lymph node biopsy confirmed anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-negative, characterized by strong CD30 expression. Peripheral blood involvement in ALK-negative ...

ALCL often responds well to treatment, especially if the lymphoma cells have too much of the ALK protein. If the lymphoma returns after initial treatment, other chemo drugs (or other types of drugs) ...